SYRS - Earnings call transcript Q4 2020 | Syros Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to Syros Pharmaceuticals Fourth Quarter and Full Year 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on Investors & Media section of Syros' website at www.syros.com. Please be advised that today's call is being recorded.

Following the formal remarks, we will open the call up for your questions. like President the Investor of Syros. I'd Naomi over Relations time, Vice Aoki, Corporate this to call turn to at At Communications and

Naomi Aoki

you. is along Syros's with release future milestones section a and Thank of accomplishments. website year the anticipated we This Investors recent fourth Media release full results, www.syros.com. our on quarter press financial XXXX and morning This available at with issued &

Simonian. the begin remarks with call Nancy will We by prepared Dr.

our Chief Chief Officer; Officer; Executive David Roth, Financial Our Ferra, Joe Chief Medical our Dr. and Officer.

call We open Springhorn, question. then are our and will Olson, Business available Chief Chief Officer; the also Jeremy for Dr. be Dr. call the Q&A. will and Eric on Officer Scientific for our

cannot our turn over any would forward-looking date. or views should highly and which represent everyone other conference now our set or obligation revise expressed on and we including those Report third-parties and which call of I and that not will to any uncertain of operations, statements extent future. to begin, We statements our statement today, we this like predicted depend from differ Form to which any relied Before subsequent we the the In any XX-K made in forward-looking be we call COVID-XX Any as of outbreak Actual we forward-looking a events to include make SEC the as remind our of this rely, on forward-looking results statements. could implied call as are by particular, this with future those any forth Annual materially result impact those morning, I would may of or with factors, representing to continues risks, Risk views filed update filings will that and make section the upon on Nancy. to the only various on that on confidence. uncertainties specifically statement. development, Factors' disclaim other the like in be as

Nancy Simonian

Naomi. we progress. good for marked remarkable you everyone. joining Thanks, our recent of a today progress year for as morning, XXXX Thank Syros. And us review

Our key vision monogenic our growth. which makes achieving to in We with company we In our three on fortified And toward has recent enduring profound focused great that living a acquisition the SY-XXXX. of a people made proceeds to cancer significant and difference resulted for We cash financings, $XXX been diseases. that always gross build through and our months, strategic fuel goal. portfolio million. stage in clinical of expanded two over position priorities with we strides together

we on a enter with against company. we we into goal laid the a last Syros commercial-stage XXXX, executing focused biopharmaceutical out of are year, maturing strategy rapidly ambitious As

of first in the XXXX, for next MDS. the the strengthening a three of myelodysplastic progress through these our Phase including we quarter, fourth on X registration-enabling hematology support or patients steps XXXX. new made targeted priorities. of three to for inhibition difficult-to-treat building in rooted leveraging hematologic In support leading the engine franchise is a cancer discovery strategy long-term pipeline to of selected CDK our and disorders, our on Our therapies our for a sustainable gene franchise acquisition that data tremendous trial syndrome growth. robust with Advancing priorities, clinical announcement control And foundational leadership fuel RARA-positive and in

Let ATO, form novel is in or December. me acquired trioxide acute of promyelocytic leukemia a from or XXXX with Orsenix APL. XXXX, patients arsenic with we begin for which

with APL and quickly huge EU people approximately on standard US know XXXX Based diagnosed everything program. provide market, the X,XXX of year. the frontline become the benefit this the the a enthusiasm about we excited each about incredibly overwhelming care and and has this believe to of in physician, are We we who potential for are the

But As of is infusions you current daily, than know, with enormously is ATO of combination up to curative for many patients. in APL, treatment the more comes is hour to with XXX XX% two The ATRA treatment four over first transformative of course burden. for therapy year. it a which IV an heavy

As could in We the reduce believe of study enable file confirmation followed NDA a XXXX treatment and an Phase agent, plan second in X APL next year, oral trial a Phase plus X could of healthcare us the broadly a on intense XXXX. early the by an of burden to ATRA frontline successful we patients as to XXXX as initiate believe more We the on half dose dramatically system. study year.

development profile confidence Turning a and path us RARA-positive mature XXXX, for patients across patient RARA-positive, which we or with XXXX, underserved well-tolerated newly of with patients with as MDS safety acute XXXX in compelling targeted care profile and activity The could leukemia compelling demonstrated serve of presented further myeloid oral unfit the ASH, gives to provide that populations. clinical activity AML. at an a therapy data multiple clear or foundation for AML diagnosed

next are clinical hard RARA-positive XXXX patients. for to execute studies on with of We wave working our

Phase a We of enrollment. in pleased XXXX. diagnosed successful, could trial open in X NDA newly now are this MDS higher-risk to and second If azacitidine RARA-positive, for enable report trial XXXX is that our filing

diagnosed venetoclax to evaluating RARA-positive, XXXX of half plus initiate on the and We in in AML Phase a study track randomized triplet regimen the X newly unfit this azacitidine of second year. also remain

populations to needs. us infrastructure opportunity second capabilities XXXX earlier advancing inhibitor an view assets, and address which continue our the our our build highly selected together, synergies hematologic Taken and CDK high expertise we as pipeline. against out franchise, progress with third existing in strategic disorders, and commercial XXXX and capitalize on leverage complementary to In parallel, make genomically-defined by priorities, is our to we stage we unmet provide medical patient three

ongoing promising trial. at our the for in we presented that actively EORTC-NCI-AACR Following Phase enroll October XXXX Symposia XXXX, X data patients initial we to continue in

from and to expansion in in the quarter of XXXX. third trial the additional on into of activity track the enter to this data are data including phase We dose half the escalation clinical second report study,

many that and next InCyte, look offers efforts partnerships Blood to and patients. distinct discovery full potentially continues early-stage of forward targets our the to most and including in working CDKXX. A discovery-stage of diseases, therapeutic enable from accelerate engine. our which Additionally, transcriptional member to reach CDKX our CDK nominating inhibition Therapeutics us We in hard advanced pipeline development two rich control platform opportunities monogenic gene power with our our Global candidate exploit program, preclinical XXXX. cancer a fuel The to and our our more expand we to Today, family are which

to moment a my thank call at Before over let David, colleagues turning take me the to Syros.

I not of As enabled a XXXX the firmly as let review over both believe our clinical more to be the MDS a XXXX make or and was our in tremendous which and my ones. people, and from recent for year, David? that across that, and with prouder programs. our excellent us could our we of XXXX here in well appreciative dedication, the all colleagues months distinguished of resilience to the Syros. their turn progress good collaboration have remained companies difficult great internally challenging. continued team for work, have know, each hard With initial for partners David call program And at and Board me to preclinical next I steps across data AML. as we have

David Roth

to with good lack We due diagnosed safety patients, make of need to Thank effective a there's and as options, it unfit with be in of designed disease X The with efficacy tolerability at a MDS from meaningful care of efficacy We phenotype trial attributes, XXXX's of therapy. The believe to you, unique Phase opportunity opportunity constellation patients profile, and well a population, was AML. AML patient of differentiated challenges thousands conviction of better that the included The our RARA-positives, our therapy as trial believe trial the continue or Nancy. presented robust benefit resistant And data to oral including targeted XXXX X is and its RARA-positive refractory AML. XXXX for Phase patients ASH, further that tolerability newly XX% of assess morning, either relapsed distinguished populations in underserved across or RARA-negative, XXXX. significant delivery, in options. highly standard strengthen both everyone. many we and are combination a RARA-positive Approximately both patients to patient both and azacitidine.

meaningful As durability. a Nancy alluded well to clinically rates high to complete response earlier, showed the as in data and rapid response time patients RARA-positive as

myelosuppression, profile life. tolerability combination these clinical events were their of azacitidine seen been not has were therapies in either increased Rates in generally comparable azacitidine well-tolerated disease who XXXX azacitidine patients populations, alone. and is toxicities single-agent generally beyond evidence including important control with or the prior was The neutropenia adverse XXXX of and elderly these no what consistent with need anemia their impact to of experience. so with quality of to and and patient Importantly,

unfit also translational likely resistant data patients not We and the patients enriches to standard that RARA to the also selects likely to suggesting XXXX, venetoclax respond ASH, to at combination most azacitidine for in monocytic studies or newly of show therapy. to refractory enriched of XX% of of VenAZA the these care AML, a as frontline emergence remain patients diagnosed patients form are VenAZA. AML. only new biomarker for for presented but Despite of Recent be over

or for most AML, both a RARA-positive are patients and AML have of of later Based to a those with could both be including of these VenAZA. we we stages to resistant that Our AML benefit that CR Cri compelling development and are data in forward aza data, XXXX have combination patients, likely and XXXX indications. suggesting form believe a who the and advancing achieved of clear into XXXX MDS, this path in show who on we

with represents We opportunity is combination in This newly diagnosed, me aza. the three MDS. for for begin with ideal believe higher-risk MDS XXXX Let reasons.

MDS to AML, a continuum in blasts and largely two but First, bone closely percent on distinguished are the the marrow. higher-risk exist diseases by is related

There's including in from overall progressed increasing disease-related this hematologic and half In without all significant higher-risk more morbidity chronic disease. its with profile, combinability XXXX's about AML. particularly cytopenias, making patients MDS aza mortality fact, eventually attracted toxicities, of to tolerability

blast XXXX close responses aza in to on we've high higher-risk is and disease rates which Second, single-agent the in MDS, complete AML, MDS activity count combination in continuum. seen low of with

are newly Phase agents of months overall median offer XX of in survival Hypomethylating initiated low to our diagnosed the with the Third, We standard CR the with of current XXXX, to set higher-risk combination recently RARA-positive, new we a a range trial feedback azacitidine either rates they patients endpoint primary opportunity in from The months. X the and response standard, care. XX have MDS of This patients to by rate, enroll or in actively complete full will we receive this XXX support XXXX trial azacitidine could X:X patient the and trial randomized be approval alone. accelerated FDA population. and or patients. believe approximately are screening which azacitidine informed will in

newly population approach is a plan rationale in data approximately alone, patients. the compared second based with XXXX VenAZA linking to biomarker trial Moving of VenAZA, plus heterogeneity to We also simple. triplet in this in us is AML, think the of RARA-positive VenAZA to year, the resistance multipronged we'd diagnosed of for upfront initiate a the The allows unfit patient to evaluating best randomized RARA study the that approach address AML Phase the AML. on X XX regimen the half to this

present populations cells standards strategy progress who that to disease to likelihood with results. more few and the believe durable deeper In on financial by MDS targeting lie both Joe excited to of new XXXX potential development. reduce AML, to the may potential you and help currently the as year that, to With these continue emergence I I'm the and XXXX over of let resistant increasing to through that updating look clinical the full move be leukemia fourth and Our monocytic the me turn simultaneously has care quarter our outset, responses. and we of ahead also call our about patients. targeted to patients options, have opportunities thus forward review set we closing, the of triplet for non-monocytic at has

Joe Ferra

David. you, Thank

our a are completed strong our $XX.X a from million completed We placement. a extend million entering we these January, in financial position. private public Together, XXXX offering the In financings and we December, $XX.X us hematology in proceeds along full inhibition, into gene in franchises XXXX unlock and our of strategic to anticipated allow priorities, while three discovery invest to engine. building and continuing the CDK cash control potential runway

our to new grateful are their investors continued existing and We for support.

million $XX.X equivalents quarter compared cash, to cash XXXX now full financial and Turning the with with million in ended $XXX fourth our XXXX. results. and at year securities, marketable of We XXXX end

quarter We of revenue January $X.X million XXXX consisting not offering. in Our proceeds InCyte. recognized collaboration million cash and from XXst, our our with XXXX, from does from the follow-on December fourth collaboration our position as $X.X XXXX, GBT $X.X in include of with of million

XXXX, in our full the collaboration revenue, our $XX.X of we and consisting with GBT For $XX.X collaboration under million year recognized under with million InCyte. million $X.X

XXXX For full the entirely quarter million, year Orsenix XXXX recognized advancement the year our All of and increase to clinical the XXXX our our expenses $X.X under G&A $XX.X fourth million earned R&D This XXXX, quarter collaboration million million and respectively. of to for $X.X of million in fourth was XXXX as XXXX, quarter for in primarily the compared million as year full $XX.X million full continued $X XXXX, the and $XX quarter the expenses within in year the and fourth trials were fourth full paid of and we million XXXX acquisition for well and the XXXX $XX.X of revenues preclinical as $XX of due and were InCyte. million the XXXX. the from for $XX.X programs. XXXX. for

G&A quarter fourth million For $XX.X million and the were for expenses year. for the XXXX, our $X.X full

of same a reported per $XX.X net per period share, net compared quarter a the Finally, million $XX.X in we $X.XX share loss loss fourth for the to for $X.XX or XXXX. million of or

share million Thank the net full over compared much. turn to loss for $X.XX net per XXXX. $X.XX full the call $XX.X per of or a $XX was questions. year very With the I'll for or XXXX that, year share, loss Our for operator the to million you

Operator

line from Cowen. Phil go Thank I the you, our of sir. show [Operator question from Instructions] Please Nadeau first ahead. comes

Phil Nadeau

just Good progress. for that on congrats the my morning. described. A Thanks few you taking questions on the trials and

light sounds depth I perhaps going where some progression First, choice endpoint randomized and MRD you're be missed endpoint wouldn't looking of at primary free Phase Can need survival. that So CR plus, of even X, you it like your hear I of the like for the endpoint. correct responses? - fact durability rate be? didn't in the or your Maybe actually to the is discuss you

Nancy Simonian

Thanks.

question. So I'm to going to David. talk ahead, to have that David to you. answer Great Go

David Roth

You know, thanks, Phil.

with patients resistance by have that aza. phenotype, demonstrated X we with RARA-positive of AML, in been venetoclax know of the to venetoclax majority this the triplet demonstrated and randomized just correlate the RARA-positive, has with remind to so is context, you to you for the provide AML of and aza. we data that very And to And rate. deliver be know, to newly compared the that ASH that venetoclax the clinical Meeting, well reflect just And complete control diagnosed independent unfit this primary is our that, the plus the composite to arm, presented we response going and just we a to is from monocytic And endpoint triplet which you comparing groups Phase treatment XXXX VenAZA. aza to activity believe which will this at multiple expect rate the again,

technical anticipate advantage into would So, approach. doublet as control expect you for population, arm clinic, than performance the randomized of a might give a what the know, if do we it less the us generally that that we of might, translates for think and well in this this we would

Phil Nadeau

at as exist from there the patient Is way population? that this in look of clones you the MRD any could differentiate leukemia to markers normal endpoint an

David Roth

survival. there's And, Absolutely. response a into the that and the you of and response, lot seeing long-term in duration translates at know, interest how MRD. of One could the the certainly of obviously, depth look

or the to almost cytogenetic approximately say in I you for demonstrated that program, molecular planned know, know, VenAZA. CR primary responses RARA-positive And diagnosed our response will CRs. the go-forward very a newly with in CRis, you of program which high consistent XX% is overall deep current against know, endpoint were all XX%were, we composite those XX%, in rate AML, about You of

path So our appropriate program current really newly this and for the data AML. forward predicting the next you diagnosed about know know steps we feeling are and in good you

Phil Nadeau

very That's - very helpful. happy

in Second or disclosed X of rate assuming the are disclose study question the What what's to control arm powering detect Have to be CR the on MDS. that And willing high-risk for versus the is the Phase treatment? you you you trial? would power difference?

David Roth

Yeah.

endpoint, So all take of patients RARA-positive, by X:X FDA. XXX we and detail, focus know XXXX complete say to on forward, level from the versus primary It's aza. responses, feedback plus we is that haven't know what the can aza information this plan the using a provided I you is, that it's randomized informed you with CR

really in feeling and we've the we're way confident good designed about the So that. which strategy in

Phil Nadeau

last And from question Great. then us.

In QX, of of to give in tumor in us for terms can what you type? sense advance XXXX some you need continuing indication see in coming proof-of-concept XXXX's to data that to an order

David Roth

So, XXXX, that is again, of inhibitor, ENA presented X. data coming our data early that this selective we at CDKX our out the Phase was so

data. know, you advancing various in And escalating in seven the in indications. days for have As reported we're know, stage two dose We're setting various seven program evaluating our, on escalation, the we and tumor you off we types regimens, off, doses. tolerable. tolerable safety on continuing days and specific five certainly or context we pleased, demonstrated which populations very demonstrate doses we're of were that in will be by ability patient at which to simulation combinations Obviously, have proof-of-mechanism to in achieving profile, the continue the either that in the informed a

and to study, help best inform forward, want the take at in we've I forward. it help frame this through we how activity take totality potential biological combinations think to we is the will inform to types markers that really the the PD how to next data we're the our of specific pick tumor know, steps. the looking employed generally, You And going that the

Phil Nadeau

my very for questions. Thanks helpful. That's taking

Nancy Simonian

Phil. Thanks,

Operator

Thank you.

next from Please Ted go ahead. question the Our Sandler. Piper of comes line from Tenthoff

Ted Tenthoff

breast very been up you sense potential a path? And in of to [ph] lot wanted ask much. for of congrats about about There's changing changing to going thank Great, much. development cancer a landscape, there. so the and sort sort you general, XXXX wanted the [compound] and the your set see on the Thanks just this thinking path of you on year. progress all the I get in expectations and

Nancy Simonian

Ted. Yeah,

- this the are fulvestrant, we could tumors. target, breast. in cancer, as negative including obviously, suggests across know of for on multiple the study, single know, both with triple difficult-to-treat with the whole HR-positive And data that You work single-agent excited we're you remain different XXXX, very about escalation opportunity our as a including examining tumor well breast types, dose patients, range

unmet So if go-forward going that medical said the we population, and we're during need in that places earlier, emerging be at to optimal generating the and think towards where as patient plan escalation, a take it David some proof-of-concept And the is the what combination that about dose of forward expansion, else looking get are to commercialization. the to we're to in space? forward data

we're up to really opportunity And, trial and But landscape. happening that aware coming also there's therapies the including XXXX. fully breast think develop the know, from think as we a we breast novel in tumors, offers opportunities both cancer as at the So exciting for many be how is across landscape. different well space, will about of the us we what's we totality looking data but of XXXX what's tremendous with which endocrine external cancer in happening the more think in HR-positive you forward, that

Ted Tenthoff

great, you much. very awesome. Thank That's

Nancy Simonian

Ted. Thanks,

Operator

you. Thank

Securities. of JMP go ahead. from next Our Please comes question line Butler from the Jason

Jason Butler

Hi, the taking thanks for question.

standard of data XXXX there not you whether based benefit enough standard with would care? CR on little can or and us MDS, talk need I to to you're see physicians, but bit powering, care to not a a Just would of to Thanks. be would just enough change change and had what interactions be on rate your disclosing know the - you maybe about, one

Nancy Simonian

Let to going over and David. out then turn me I'm start to it

of you have the to drug the decades this one azacitidine in these problems the is is they disease. know, and sort results example. disease, provides the that you And approved cytopenias compelling of there as other require we know, space, HMAs from infection-related with quite get physicians they And limited neutropenia, find a mortality - know, new You what a we, think obviously, than related in hasn't and is, MDS, XXXX in MDS higher-risk morbidity for profiles in into of I complications as And lot know transfusions. you about have and in alone, discussion in patients of their lot or opportunity major been an these a patients.

and physicians a disease. So their think the exacerbate AML. compelling the acutely little are drug a these but and can really as efficacy, more to from doesn't have that is opportunity chronic have give patients I to profile expressed It's a they're of off - bit cytopenias us doesn't blasting like that not

profile. works is to So about and that it how really something over a me a David, that. But bit more outpatient endpoint and These well-tolerated, typically little in can if see you the wonderful physicians you feel it are CRs add well, about turn convenient. patients let as,

David Roth

at to you the collecting Fortune you of even evolution we're you for benefit. know, we accepted it's what patients, the a that's and I'm for are on you expecting. know, technically, purposes include we'll be RARA-positive you going the the obviously the know, help, I assuming, totality serve an you for XX an the swift - know, full to obtaining totality it or data accelerated that standard our of data that is no, based data. approval, And, other know, package. you're question. you our surrogate of care And as looking know, sure that CR our think And may Yeah, And is an of important that, approval long-term endpoint

evidence. convincing be we'll know, parameters You at provide looking other help will that that

of can So improvement, be so counts involves that transfusion things which for for as mentioned. normalization blood problematic like patients, the these peripheral Nancy hematologic instance, the independence,

survival things an we the of and reason into duration will response, believe compelling of adoption the and up the in will nature know, all this know, of you treatment for of these what that patients. You of roll the a drug length be

Jason Butler

Thank great. much. you Okay, very

Nancy Simonian

Thanks, Jason.

Operator

Thank you.

of the from comes go Our from question Please Breidenbach next Mark line ahead. Oppenheimer.

Mark Breidenbach

one's Hey, But with in to to MDS, an and for trial taking XXX before David. the good interim toward, full morning, just probably Phase respect are This questions. plans analysis the thanks include any my X enrolling and there patients?

David Roth

good a Yeah, question.

been details. you So very we've we, currently know, specific with not the

Our we're XXXX we've and are plans enrollment. current in that, and the be at initiated made for would that. an when open would timeframe, you you our guidance available public. us provided know, this the as we today, It's And, to haven't data we filing said know, of NDA projections proud trial, very estimates additional have point

Mark Breidenbach

to after or And going be made think do to likely are Phase you're the X you subset the expansion? narrower Or expansion tumor with escalation? all respect be narrow inclusive types dose to same understood. going more it tumor more going Okay, a XXXX, of cohorts in specific types that and into of

David Roth

the So, another good - question.

clinical trial activity. that the the know, that of we're and right data also, objectives been those help from subsequently to better to the the trial our then data of and current ENA, quarter. We additional you seeking what focus safety this plan understand, on information the to going understand, have time to have we're the a enrolled share at So to expect now, is in enrolled include for would third patients

in the half, opening about we'll second then that. So And we're these excited be expansions.

the like. be on information nature more of provided those haven't expansions what We would

I in help think decision-making. we experience generally, our inform our that to respect. look are certainly We data-driven to we

as pancreatic, you sorts lung, we of will study colorectal, have lots know, we with other how also the with you we are other single-agent combination on patients find their data ovarian have to a into know, now cancer right depending work design, But So way out. itself also focused potentially our going know explore breast is, on on fulvestrant. a that things you

time that around are you the give that expansions more on So forward. of we'll context moving the

Mark Breidenbach

Okay.

enough fair Okay, -

Nancy Simonian

if And you move expansion I'll and Mark set one a are with maybe, pretty maybe it's what more just an you - to into typical you I'll various generally, at expansion that, homogeneous add just and did we the patients. look cohorts of XXXX, that phase when know,

- I that's think we've that something done XXXX. that So it's one what expect. with And can

you you know, in cohorts. hone in next you So on, one on more based phase, populations multiple for that or as focus

Mark Breidenbach

finally, one. it, Do it. the fetal last preclinical Got you a got from inducers? to And know just have data year quick while. that heard any from we one much plans just you in So program this haven't that present hemoglobin

curious. Just Thanks.

Nancy Simonian

at data just very data, about or Therapeutics with Yeah, we collaboration productive disclosed, really we're, been And Global the Global They're partners. discovery very you Blood we're a potential going highly a presenting you partnership provide would going I say if, to to wonderful molecule, to small we but know, is not the continue really functional be about cure know, well, that. get in be have when that Blood. I'm relationship, excited opportunity to bullish it's a with

Mark Breidenbach

Okay, taking and the questions the thanks on congrats progress. so much for

Nancy Simonian

you, Mark. Sure. Thank

Operator

Thank you.

line the ahead. Please Jallah Zegbeh of go Capital. question next from ROTH comes from Our

Zegbeh Jallah

morning, Good guys.

to updates the two said think the to factors so wanted specifically, ask questions, APL had all just and I timeline excited XXXX. regarding program? Just you see in the program, then quick of XXXX it had for influencing if for progress companion the that diagnostic the any any development you

So that. to mechanics just the kind around wanted understand of

Nancy Simonian

Yeah, hey, Zegbeh.

the We've for development of patient trial launching quite we diagnostic, at because will detail. very is clinical progressing important But assay you And the of on the working end your population. that parallel diagnostic a suffice been a had parallel to that, know development in Zegbeh? yeah, the in strategy with be development. that second the RARA-positive nicely that's are the I'm part it's sorry, in the is we And we robust. haven't more of day, companion So XXXX, place very important. given it question, say development companion quite drug in clinical a

Zegbeh Jallah

the program. timeline APL for It's just about the

Nancy Simonian

Yeah.

team the be you enables just So to year, next you that of confirmation year. half done the and very a pulling we initiate gearing the trial job, in And has Syros know, up second the dose us team things X together quickly December. Phase acquired in - a to know, start remarkable the study this asset to

work, excited the both as has you the know, upon very next well. on been which manufacturing X Phase the potential everything work but the team a the cusp to and So involve be start pull know, about both together year, clinical of of pace quickly, you obviously the we're which, able a - to asset lot

feel great thing execution well. need think KOLs in I as how lot the from in think is, we've just of us And for about in there great the just that we that. got on therapy. that much a So, of field, confidence just is of the I gives underscores tremendous amount a a the this enthusiasm the other just And plan

- So

Zegbeh Jallah

Thanks -

Nancy Simonian

you That Zegbeh? question, Great to your help Okay, to awesome. answer you. talk

Operator

Our Thank comes Alliance Please next the you. ahead. question from Matthew go Instructions] of Global. [Operator line Cross from

Matthew Cross

VenAZA XXXX AML. feel to we've like ven study in Both And therapy balance aza I'm maybe to tox the about or Good there's was a then you VenAZA magrolimab was, new of as And Gilead questions the diagnosed as AML, these in add-on Phase the to from may know, backbone plus you VenAZA. one wondering from away about yesterday, I as as X, I for specific time the the relating X any positioning a anything seen to you a particular, maybe In that X and guess replace the efforts X study Thanks. the for mutant Phase of dosing some curious the order by if XXXX with? Hi, Do you're me. meaningful X I VenAZA posted out cytopenias how think such of just newly or Phase second had to manage the hypertriglyceridemia? to looking and believe, in advanced? at in plus been couple settings VenAZA, triplet combine to decided thanks with all. compared adding morning considerations study landscape of an I taking guess NTPXX, shifted have certain risk a

David Roth

initial the question the with start related to that of I'll maybe the part dosing. and so Okay,

have to that focus that a you that haven't all and this trial help you you be progress very that great going half know, to the planned it's sort start with earlier of venetoclax the fairly a where question designed seen it's deliver the at But that would input XXXX on you detail we've That and we it's you that just provided together And drug. the And there. venetoclax getting also increases plan. year, suggest making to enthusiasm mentioned to be haven't known of to proceed not straightforward of plus concerning be to know, The in myelosuppressive So, dosing think ability And, of use which and one additive we we contexts. to with going don't strategy. are be versus we're with know, of is on experts aza and remind populations in great is be anticipate you're aza. second various on I cadre to in a the lead at of safety from, how brief run important dosed. to us. issues of going safety we'll to affords going I strategy little it's we're in it's the why think these SY-XXXX, into, so challenges more a know, going specifics profile important generally We our combination that you I toxicities, conviction for know, used attributes well-tolerated that,

to we our that's expect that and but know going initial you sure with, through do know forward start so Ts just authorizing we you to are know, phase. you cross start this move to that, So, make efficiently why, to

have this the asked don't we're events within veterans of abnormalities - expect triglycerides, cause question problems laboratory adverse And been population that know you know have largely and quiet, those maybe know, particular speak. you so on. a to you we to that You focused been, clinically in

Nancy Simonian

And then the in combinations. field of on know, is aspect the just where other you going

the is obviously, dynamic a very is this AML know, space. space You

other will that the We of with continue opportunity kind standard action, is care great are - and different believe currently we that, important of drugs. of has standard going an feel to combine XXXX we of it care a toxicities forward. be mechanism drugs. the it novel combines, is to confident thing really associated about quite VenAZA have the multiple it It's doesn't of But the well

or of to an it overlapping things variety of days doublets the to additional then things. us triplets. we how as just were emerging, look also think and about was in so we to emerging think will that, to provide think a are with different part triplets were a couple Velcade of of and I doublets at for field, the we were And we that toxicities, exactly as XXXX And of didn't opportunity a have that have back myeloma, development and sort combining able of and in backbone,

competitive and us ensure strategy to going landscape in So future. very to commercial will is we carefully the where that market best that have watching a we position be the are the

Matthew Cross

Thanks, for the addressing the the Great, okay. the Appreciate reminders No, questions. insight guys. and designs. thanks on

Nancy Simonian

Thank you, Matt.

Operator

further the this no I'd Dr. like to questions remarks. call in Nancy closing to Simonian, show At turn back I you. time, Thank CEO the queue. for

Nancy Simonian

operator. for and you, you for to today thank of Thank continued all Syros. support want joining us your I

with profound Thank We are cancer toward advancing into three integrated diseases. focused a executing make for fully a our so much. that priorities, targeted and with biopharmaceutical Syros of against medicines and portfolio building difference strategic people a on company monogenic of vision you

Operator

this gentlemen, call. conference you concludes participating. Thank and Ladies for today's

disconnect. now may You

Syros Pharmaceuticals (SYRS) 4 Mar 212020 Q4 Earnings call transcript